Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06271252 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
A Phase 1 study of Cardiovascular Diseases and Neoplasms, sponsored by OriCell Therapeutics Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT06271252 is a Phase 1 study of Cardiovascular Diseases and Neoplasms that is actively recruiting participants, run by OriCell Therapeutics Co.. The registered enrollment target is 81 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06271252, a Phase 1 study of Cardiovascular Diseases and Neoplasms, is actively recruiting participants, sponsored by OriCell Therapeutics Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study
Conditions Studied
Interventions
- DRUG OriCAR-017
Study Locations (1)
Georgia
- Northside Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2024-04-03 |
| Est. Completion | 2028-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06271252
The ClinicalTrials.gov registry entry for NCT06271252 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The listed sponsor is OriCell Therapeutics Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which OriCAR-017 is the first listed.
NCT06271252 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06271252 about?
NCT06271252 is a clinical study titled "A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study". The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study
What is the current status of trial NCT06271252?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2024-04-03. Estimated completion is 2028-04-12.
What conditions does trial NCT06271252 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Neoplasms, Vascular Diseases, Hematologic Diseases, Neoplasms by Histologic Type.
What interventions are being tested in trial NCT06271252?
The interventions under investigation include: OriCAR-017 (DRUG).
Who is sponsoring clinical trial NCT06271252?
This trial is sponsored by OriCell Therapeutics Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06271252 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Prevention of Progression of Prediabetes, Obesity and CV Risk
RECRUITING · Phase 1
-
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
RECRUITING · Phase 1
-
AB-1002 in Patients With Class III Heart Failure
ACTIVE NOT RECRUITING · Phase 1
-
Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease
COMPLETED · Phase 1
-
MRI-Guided Balloon Angioplasty to Treat Blood Flow Blockage in the Legs
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.